Elevated plasma levels of calcitonin gene-related peptide in individuals with rosacea: A cross-sectional case–control study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Understanding the role of calcitonin gene-related peptide (CGRP) in the pathogenesis of rosacea might provide new therapeutic avenues for individuals with this disease.
Objective
To compare plasma levels of CGRP between individuals with rosacea and healthy controls.
Methods
In this cross-sectional case–control study conducted in Copenhagen, Denmark, we collected blood samples from the antecubital vein from adults with rosacea and from healthy controls.
Results
We enrolled 123 individuals with rosacea and 68 healthy controls. After adjusting for age and sex, plasma levels of CGRP were significantly higher in individuals with rosacea (mean, 95% confidence interval: 140.21 pmol/L, 128.50–151.92 pmol/L), compared with controls (110.77 pmol/L, 99.91–120.14 pmol/L, p = 0.002). Plasma levels of CGRP were not affected by age, sex, BMI, concomitant migraine, rosacea sub- or phenotype, concomitant disease or current treatment.
Limitations
Participants were not age-, sex- and BMI-matched.
Conclusions and Relevance
Elevated plasma levels of CGRP in individuals with rosacea suggest a role of CGRP in the pathogenesis of rosacea. Targeting CGRP signalling might hold therapeutic promise in people affected by this disease.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of the European Academy of Dermatology and Venereology |
| ISSN | 0926-9959 |
| DOI | |
| Status | Accepteret/In press - 2024 |
Bibliografisk note
Funding Information:
Nita K. F. Wienholtz reports no conflicts of interest. Casper E. Christensen reports personal fees as consultant and speaker from Teva pharmaceuticals. H\u00E5kan Ashina reports personal fees from Teva, outside of the submitted work. Niklas R. J\u00F8rgensen reports no conflict of interest. Alexander Egeberg has received honoraria as consultant and/or speaker from AbbVie, Almirall, Bristol\u2010Meyers Squibb, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals and being an employee of LEO pharma outside the submitted work. Jacob P. Thyssen is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, ASLAN Pharmaceuticals, Union Therapeutics, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron and Sanofi Genzyme; a speaker for AbbVie, Almirall, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron and Sanofi Genzyme; has received research grants from Pfizer, Regeneron and Sanofi Genzyme and being an employee of LEO pharma outside the submitted work. Messoud Ashina reports receiving personal fees from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva Pharmaceuticals during the conduct of the study. MA reports serving as associate editor of Cephalalgia, associate editor of The Journal of Headache and Pain and associate editor of Brain.
Funding Information:
This study was supported by grants from Novo Nordisk Foundation (NNF170C0029698). MA was supported by the Lundbeck Foundation professor grant (R310\u20102018\u20103711).
Publisher Copyright:
© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
ID: 393840399